We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study.
- Authors
Gökyer, Ali; Küçükarda, Ahmet; Köstek, Osman; Hacıoğlu, Muhammet Bekir; Uzunoğlu, Sernaz; Kula, Osman; Kurt, Nazmi; Üstündağ, Sedat; Erdoğan, Bülent; Çiçin, İrfan
- Abstract
Objectives: Contrast nephropathy risk has been increasing in cancer patients. Nephrotoxic side effects of anti-vascular endothelial growth factor/receptor (anti-VEGF/R) drugs used in oncologic treatment are also prominent. The purpose of this study was to identify the possible association among anti-VEGF/R drugs use and development of the contrast-induced nephropathy (CIN) in patients with cancers. Methods: A total of 92 patients were included in this prospective cross-sectional study. Patients whose glomerular filtration rate (GFR) of < 50 ml/min, hemoglobin of < 10 g/dl, and eastern cooperative oncology group (ECOG) score of ≥ 2 and had received nephrotoxic drugs were not included in the study. Blood samples were collected baseline at pre computed tomography (CT) and day 2, day 3 and day 7 later CT imaging. CIN was defined as either an increased serum creatinine value of 0.5 mg/dl or increased 25% to baseline. CIN frequency between groups receivingand not receiving anti-VEGF/R was compared using the chi-squared test. CIN frequency between bevacizumab and other anti-VEGF/R was also analyzed. Results: There were 39 patients in the anti-VEGF/R (+) group and 53 patients in the anti-VEGF/R (−) group. Eleven patients (28%) in the anti-VEGF/R (+) group and 3 patients (5.6%) in the anti-VEGF/R (−) group had CIN (p = 0.006). In the anti-VEGF/R (+) group, 23 patients received bevacizumab (combined with FOLFOX/FOLFIRI), while 16 patients received other anti-VEGF/R (sunitinib, axitinib, regorafenib, aflibercept) effective treatments. CIN ratio in patients who received bevacizumab or other anti-VEGFR therapy was similar (p = 0 = 50). Of the patients, one patient had acute kidney injury leading to death. Conclusion: CIN was significantly more frequent in cancer patients who receiving anti-VEGF/R drugs than those not receiving anti-VEGF/R drugs.
- Subjects
ENDOTHELIAL growth factors; CANCER patients; LONGITUDINAL method; SPIRAL computed tomography; GLOMERULAR filtration rate
- Publication
International Journal of Clinical Oncology, 2020, Vol 25, Issue 10, p1757
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-020-01729-3